Publicacións (25) Publicacións de Maria Vieito Amor

2024

  1. Long-term sequelae and quality of life after childhood-onset craniopharyngioma: Results of a Spanish multicenter study

    Pediatric Blood and Cancer, Vol. 71, Núm. 12

2023

  1. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

    Med, Vol. 4, Núm. 10, pp. 710-727.e5

  2. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

    Nature communications, Vol. 14, Núm. 1, pp. 1359

  3. Review of the remission and management of a cancer related pain population to a pain unit. What can we improve?

    Revista de la Sociedad Espanola del Dolor, Vol. 30, Núm. 1, pp. 7-14

2022

  1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  2. Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs)

    European Journal of Cancer, Vol. 174, pp. S70

  3. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

    Neuro-Oncology Advances, Vol. 4, Núm. 1

2021

  1. Adaptation of the pain management service complejo hospitalario de vigo to the sars-cov-2 pandemic

    Revista de la Sociedad Espanola del Dolor, Vol. 27

  2. First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676

  3. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

    European Journal of Cancer, Vol. 155, pp. 168-178

  4. SEOM clinical guideline for management of adult medulloblastoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947

2020

  1. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria

    Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855

  2. Development of pharmacodynamic biomarkers for phase I trials

    Phase I Oncology Drug Development (Springer International Publishing), pp. 139-158

  3. Global gene expression characterization of circulating tumor cells in metastasic castration-resistant prostate cancer patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-14

  4. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

    Annals of Oncology, Vol. 31, Núm. 6, pp. 780-788

2017

  1. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients

    Oncotarget, Vol. 8, Núm. 33, pp. 54708-54721

2016

  1. Clinical application of circulating tumour cells in prostate cancer: From bench to bedside and back

    International Journal of Molecular Sciences, Vol. 17, Núm. 9

  2. Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer

    Scientific Reports, Vol. 6

2014

  1. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer

    International Journal of Cancer, Vol. 135, Núm. 11, pp. 2633-2643

  2. Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment

    Cancers, Vol. 6, Núm. 1, pp. 153-165